Zoledronate : Efficacy and safetyREID, Ian R.Journal of bone and mineral research (Print). 2006, Vol 21, issn 0884-0431, P83-P87, SUP2Conference Paper

Successful treatment of multicentric reticulohistiocytosis with alendronate: Evidence for a direct effect of bisphosphonate on histiocytesGOTO, Hitoshi; INABA, Masaaki; KOBAYASHI, Keisuke et al.Arthritis and rheumatism. 2003, Vol 48, Num 12, pp 3538-3541, issn 0004-3591, 4 p.Article

Effects of ibandronate on bone quality : Preclinical studiesBAUSS, F; DEMPSTER, D. W.Bone (New York, NY). 2007, Vol 40, Num 2, pp 265-273, issn 8756-3282, 9 p.Article

Ulcérations buccales dues aux diphosphonates = Severe oral mucosa ulcerations induced by biphosphonatesLa Revue Prescrire. 2007, Vol 27, Num 283, pp 358-358, issn 0247-7750, 1 p.Article

Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronateMAVRAGANI, C. P; BATZIOU, K; ARONI, K et al.Annals of the rheumatic diseases. 2005, Vol 64, Num 10, pp 1521-1522, issn 0003-4967, 2 p.Article

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis : a pilot studyRINGE, J. D; DORST, A; FABER, H et al.Rheumatology international (Berlin. Print). 2005, Vol 25, Num 4, pp 296-300, issn 0172-8172, 5 p.Article

Severely suppressed bone turnover : A potential complication of alendronate therapyODVINA, Clarita V; ZERWEKH, Joseph E; SUDHAKER RAO, D et al.The Journal of clinical endocrinology and metabolism. 2005, Vol 90, Num 3, pp 1294-1301, issn 0021-972X, 8 p.Article

Bioequivalence studies on bisphosphonates: The example of alendronateLAINESSE, Audrey; OZALP, Yildiz; HONG WONG et al.Arzneimittel-Forschung. 2004, Vol 54, Num 9A, pp 569-572, issn 0004-4172, 4 p.Article

Bisphosphonates for the treatment of Charcot neuroarthropathyANDERSON, John J; WOELFFER, Kirk E; HOLTZMAN, John J et al.The Journal of foot and ankle surgery. 2004, Vol 43, Num 5, pp 285-289, issn 1067-2516, 5 p.Article

What can nano-chemistry offer to the paint industry ?FELHÖSI, I; TELEGDI, J; PAPP, K et al.Die Makromolekulare Chemie. Macromolecular symposia. 2002, pp 305-315, issn 0258-0322, isbn 3-527-30477-7Conference Paper

Effect of precipitating conditions on the formation of calcium-HEDP precipitatesBROWNING, F. H; FOGLER, H. S.Langmuir. 1996, Vol 12, Num 21, pp 5231-5238, issn 0743-7463Article

Effect of topical alendronate treatment on fixation of implants inserted with bone compactionJAKOBSEN, Thomas; KOLD, Søren; BECHTOLD, Joan E et al.Clinical orthopaedics and related research. 2006, Num 444, pp 229-234, issn 0009-921X, 6 p.Article

Diez casos de osteonecrosis mandíbular (ONM) asociada a bisfosfonatos = Ten cases of osteonecrosis of the jaw related with biphosphonatesFERREIRO, S. Varela; OZORES, P. Palacios; SALGADO BOQUETE, L et al.Oncología (Barcelona). 2007, Vol 30, Num 4, pp 13-21, issn 0378-4835, 9 p.Article

Ibandronate : Un nouveau bisphosphonate par voie orale = Ibandronate : a new oral bisphosphonateThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 11, pp 55-56, issn 0253-8512, 2 p.Article

Goals of treatment for Paget's disease of boneSIRIS, E. S.Journal of bone and mineral research (Print). 1999, Vol 14, pp 49-52, issn 0884-0431, SUP2Conference Paper

Les métastases osseuses : Pathogenèse et traitement par les bisphosphonates. Discussion = Bone metastasis : pathophysiology and diphosphonate treatmentBODY, J. J; GOLDMAN, M; VANDERHOEFT, P et al.Bulletin et mémoires de l'Académie Royale de Médecine de Belgique. 1997, Vol 152, Num 3, pp 169-176, issn 0377-8231Article

Metabolism of the bisphosphonate ester U-91502 in ratsSLATTER, J. G; FEENSTRA, K. L; HAUER, M. J et al.Drug metabolism and disposition. 1996, Vol 24, Num 1, pp 65-73, issn 0090-9556Article

A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD MonitoringMCNABB, Brian; VITTINGHOFF, Eric; EASTELL, Richard et al.The Journal of clinical endocrinology and metabolism. 2014, Vol 99, Num 11, pp 4094-4100, issn 0021-972X, 7 p.Article

Circulating γδ T Cells and the Risk of Acute-Phase Response After Zoledronic Acid AdministrationROSSINI, Maurizio; ADAMI, Silvano; VIAPIANA, Ombretta et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 1, pp 227-230, issn 0884-0431, 4 p.Article

The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone massANASTASILAKIS, Athanasios D; POLYZOS, Stergios A; DELAROUDIS, Sideris et al.Clinical endocrinology (Oxford. Print). 2012, Vol 77, Num 6, pp 816-822, issn 0300-0664, 7 p.Article

Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targetingNASR, Maha; AWAD, Gehanne A. S; MANSOUR, Samar et al.European journal of pharmaceutics and biopharmaceutics. 2011, Vol 79, Num 3, pp 601-611, issn 0939-6411, 11 p.Article

Dose-dependent differential effects of risedronate on gene expression in osteoblastsWANG, J; STERN, P. H.Biochemical pharmacology. 2011, Vol 81, Num 8, pp 1036-1042, issn 0006-2952, 7 p.Article

Proton Pump Inhibitor Use and the Antifracture Efficacy of AlendronateABRAHAMSEN, Bo; EIKEN, Pia; EASTELL, Richard et al.Archives of internal medicine (1960). 2011, Vol 171, Num 11, pp 998-1004, issn 0003-9926, 7 p.Article

Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case seriesSIVENDRAN, Shanthi; HARVEY, Harold; LIPTON, Allan et al.International journal of hematology. 2011, Vol 93, Num 6, pp 782-786, issn 0925-5710, 5 p.Article

The Effect of Weekly Risedronate on Periprosthetic Bone Resorption Following Total Hip Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled TrialOG, Sköldenberg; MO, Salemyr; HS, Boden et al.Orthopedics (Thorofare). 2011, Vol 34, Num 12, issn 0147-7447, p. 989Article